Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
Venetoclax In Combination with ASTX727, an All-Oral TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY- MDS/MPN): a Randomized, Phase 2 trial
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 22, 2025
Evaluating the prevalence of metabolic dysfunction associated steatotic liver disease (MASLD) during pregnancy and its influence on pregnancy outcomes and postpartum maternal health
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 29, 2025
A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2025
Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients with Motor Complications
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2025
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2025
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab in Combination With Pola-R-CHP Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 22, 2025
Serranator OCT: Understanding the Mechanism of Action of Serration Angioplasty by Serranator Versus Conventional Balloon Angioplasty for below-the Knee (BTK) Artery Disease Using Optical Coherence Tomography (OCT)
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2025
Boomerang-Pivotal Multicenter Trial of the Boomerang Catheter for Percutaneous Deep Vein Arterialization (pDVA)
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2025
Esprit BTK Post-Approval Study (PAS)
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2025
Elegance: Drug-Eluting Registry-Real-World Treatment of Lesions in the Peripheral Vasculature
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2025